HIV, HBV, HCV Coinfections
AASLD LiverLearning®, Douglas Dieterich, 154676
Approach to the Patient with Iron Overload
AASLD LiverLearning®, Kris Kowdley, 154675
Adult Living Donor Liver Transplant: Donor and Recipient Considerations
AASLD LiverLearning®, Rebecca Duke, 154674
Awarded Poster Presentation
AASLD LiverLearning®, Anna Hefner, 154673
iPSC and Disease Modeling in the Liver
AASLD LiverLearning®, Ludovic Vallier, 154691
The Impact of Cirrhotic PVT on Liver Transplant: A Medical Perspective
AASLD LiverLearning®, Nicolas Intagliata, 154701
Complications of Cholestatic Liver Diseases
AASLD LiverLearning®, Cynthia Levy, 154672
iPSCs and Correction of A1AT Deficiency
AASLD LiverLearning®, Andrew Wilson, 154690
Cholangiocytes From iPSC
AASLD LiverLearning®, Romina Fiorotto, 155708
Treatment of PVT in Cirrhosis: Who, When and How
AASLD LiverLearning®, Juan Carlos Garcia-Pagan, 154700
Etiology of Liver Disease: Does it Make a Clinical Difference?
AASLD LiverLearning®, Jordi Bruix, 154712
Hepatocytes From iPSC
AASLD LiverLearning®, Holger Willenbring, 154688
Diagnosis and Natural History of PVT In Cirrhosis
AASLD LiverLearning®, Dominique-Charles Valla, 154699
Statins and Metformin as Chemoprevention for HCC
AASLD LiverLearning®, Lewis Roberts, 154711
Panel Discussion
AASLD LiverLearning®, Session Speakers, 155768
Future Landscape With HCV Therapy
AASLD LiverLearning®, Fred Poordad, 154669
Session II: Epidemiology and Clinical Insights
AASLD LiverLearning®, Gregory Gores, 154709
Liver Transplantation for NASH Associated HCC
AASLD LiverLearning®, Kimberly Ann Brown, 154710
Cirrhosis – Beyond Portal Hypertension
AASLD LiverLearning®, Lucy Mathew, 154668
Engineering of the Liver via iPSC
AASLD LiverLearning®, Takanori Takebe, 154685
Does Prophylactic Anticoagulation Alter the Course of Cirrhosis? Lessons from Prophylactic Trials
AASLD LiverLearning®, ERICA VILLA, 154698
Natural History: The Magnitude of the Problem from Hepatology Clinic Perspective
AASLD LiverLearning®, Augusto Villanueva, 154708
Parenchymal Extinction in 2016: What is the Human Evidence?
AASLD LiverLearning®, Ian R. Wanless, 154697
Management of Metabolic Syndrome and NASH
AASLD LiverLearning®, Rohit Loomba, 154667
Induced Pluripotent Stem Cells in the Future of Gastroenterology/Hepatology
AASLD LiverLearning®, Stephen Duncan, 154684
Diabetes Associated HCC: The Molecular Profile
AASLD LiverLearning®, Jessica Zucman-Rossi, 154707
Coagulation, Thrombin, Fibrosis and Inflammatory Pathways in the Liver
AASLD LiverLearning®, James Luyendyk, 154696
NAFLD Promotes HCC by Causing CD4(+)T Cell Depletion
AASLD LiverLearning®, Tim Greten, 154706
Developmental Biology: The Foundation for Gastrointestinal Tissue Engineering
AASLD LiverLearning®, James Wells, 154681
Hepatology Associates Course: Session I
AASLD LiverLearning®, Lisa Richards, 154664
Managing Alcoholic Hepatitis
AASLD LiverLearning®, Vijay Shah, 154666
Cirrhosis as a Prothrombotic State: Overview and Update
AASLD LiverLearning®, Ton Lisman, 154695
Serum Dickkopf-1 as a novel biomarker for hepatocellular carcinoma with stem cell features
AASLD LiverLearning®, Hajime Sunagozaka, 144132
Deregulation of the immune-related transcriptome in Resected human Biliary Tract Cancers
AASLD LiverLearning®, Chiara Braconi, 144133
BAFF, BAFF promoter and BAFF receptor allelic variants in HCV-related Mixed Cryoglobulinemia and Non Hodgkin’s Lymphoma.
AASLD LiverLearning®, Giorgia Ceccotti, 144389
FGF19 immunostaining as biomarker for trial enrichment testing FGFR4 inhibitors in HCC
AASLD LiverLearning®, Agrin Moeini, 144134
Occurrence of polymorphisms and resistant mutations in the NS3, NS5A and NS5B genes of HCV based on sequences deposited in the European Hepatitis C Virus Database (euHCVdb).
AASLD LiverLearning®, Dimas Kliemann, 144390
Cost-effectiveness of a risk-stratified hepatocellular carcinoma surveillance strategy in patients with cirrhosis
AASLD LiverLearning®, Yujin Hoshida, 144148
Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry
AASLD LiverLearning®, Su Jong Yu, 144149
Quantitative molecular magnetic resonance imaging of fibrogenesis and fat content in the liver during non-alcoholic steatohepatitis
AASLD LiverLearning®, Bryan Fuchs, 144405
Hyperlipidemia and Non-Alcoholic Steatohepatitis are Risk Factors for Hepatocellular Carcinoma Development in the Absence of Cirrhosis
AASLD LiverLearning®, Jennifer Phan, 144150
Aging aggravates alcoholic liver injury and fibrosis in mice by downregulating Sirtuin1expressionin the liver
AASLD LiverLearning®, Chuansheng Wang, 144406
Hepatitis C virus replication promotes p53 degradation through chaperone-mediated autophagy (CMA).
AASLD LiverLearning®, Yucel Aydin, 144164
Among Adults with Hepatocellular Carcinoma in the United States, Low Income Patients Have Significantly Lower Overall Survival Independent of Tumor Stage and Treatment Received
AASLD LiverLearning®, Melissa Yan, 144165
The FXR/TGR5 dual agonist INT-767 prevents and reverses Western diet-induced NASH and modulates major lipid metabolic pathways in mice.
AASLD LiverLearning®, Xiaoxin Wang, 144421
Biological significance of a disintegrin and metalloproteinase 21 expression in hepatocellular carcinoma
AASLD LiverLearning®, Masaaki Takamura, 144166
Reduced PI3K pathway in NK cells of F4-NAFLD patients inhibited mTOR expressions and was correlated with their impaired function
AASLD LiverLearning®, Johnny Amer, 144422
Success of Photodynamic Therapy in Palliating Patients With Nonresectable Cholangiocarcinoma: A Meta-Analysis and Systematic Review
AASLD LiverLearning®, Zohair Ahmed, 144180
Up-stage Treatment Migration Improved Overall Survival of Selected BCLC B and C Hepatocellular Carcinoma Patients
AASLD LiverLearning®, POH SENG TAN, 144181
Role of Dietary Fatty Acids in Liver Injury Caused by Vinyl Chloride Metabolites in Mice
AASLD LiverLearning®, Lisanne Anders, 144437
Basic Research Workshop: Program Chair
AASLD LiverLearning®, Mario Strazzabosco, 154677
Impact of age and race/ethnicity for women with gastrointestinal and hepatobiliary malignancies in the U.S.
AASLD LiverLearning®, Vicky Bhagat, 144182
Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by affecting GLP-1 and gut microbiota
AASLD LiverLearning®, Jian-Gao Fan, 144438
Aims of the Workshop
AASLD LiverLearning®, Jorge Bezerra, 154680
Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the T reatment of S mall H epatocellular C arcinoma
AASLD LiverLearning®, Huijun Xu, 144196
radiation induced liver disease after stereotactic body radiation therapy for small hepatocellular carcinoma; risk factor and clinical significance
AASLD LiverLearning®, Young Don Kim, 144197
The effects of gut microbiota and the flavin mono-oxygenase enzyme 3 (FMO3) on choline bioavailability in nonalcoholic fatty liver disease
AASLD LiverLearning®, Naim Alkhouri, 144453
Serum PEDF is an Independent Indicator of Non-Invasive Diagnosis in Non-Alcoholic Steatoheaptitis
AASLD LiverLearning®, Jingmin Zhao, 144454
Hepatitis B Reactivation Associated with Direct Acting Antiviral Therapy for Hepatitis C: A Review of Spontaneous Post-Marketing Cases
AASLD LiverLearning®, Susan Bersoff-Matcha, 154958
Hepatobiliary Neoplasia SIG: NASH and HCC: Program Chair
AASLD LiverLearning®, Lopa Mishra, 154703
Retreatment with sofosbuvir + grazoprevir + elbasvir + ribavirin of patients with Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir + ledipasvir or + daclatasvir or + simeprevir regimen (ANRS HC34 REVENGE study)
AASLD LiverLearning®, Victor de Ledinghen, 154959
Overview: The Relationship Between NASH and HCC
AASLD LiverLearning®, Hashem El-Serag, 154705
Nucleos(t)ide analogues improved survival of CHB-related HCC patients
AASLD LiverLearning®, wang yun, 144212
Patients’ misconceptions about surveillance for hepatocellular carcinoma: Education is needed.
AASLD LiverLearning®, Faydra Lieveld, 144213
Comparison of Obeticholic Acid and GFT505 (Elafibranor) for Treatment of Non-Alcoholic Steatohepatitis (NASH) in a Human In Vitro Surrogate System
AASLD LiverLearning®, Ryan Feaver, 144469
Endoglin Antibody Reduces the NAFLD Activity Score in the STAM Model of NASH and Reduces Liver Fibrosis Following Carbon Tetrachloride Treatment
AASLD LiverLearning®, Charles Theuer, 144471
A single endoscopic duodenal mucosal resurfacing procedure exerts a sustained improvement in hepatic transaminase levels in a cohort of type 2 diabetes patients
AASLD LiverLearning®, Annieke van Baar, 154974
Discovery of new non-invasive tests algorithms (NITs-Algo) for liver disease in subjects with metabolic factors, using SAF scoring system. A proof of concept demonstrating the impact of disease definitions.
AASLD LiverLearning®, Thierry Poynard, 154975
Survival analysis of single large (>5 cm) hepatocellular carcinoma patients: BCLC A versus B
AASLD LiverLearning®, Su Jong Yu, 144228
The sustained virologic response achieved by PegIFN/RBV could significantly improve survival of intermediate stage CHC-HCC patients receiving TACE
AASLD LiverLearning®, Wei Teng, 144229
Serum Proteomic Biomarkers of Hepatocellular Carcinoma Associated with Nonalcoholic Fatty Liver Diseases in a Newly Established Pig Model
AASLD LiverLearning®, Naohiko Namakura, 144486
3-mercaptopyruvate Sulfurtransferase Exacerbates Nonalcoholic Fatty Liver Disease Via the Inhibition of Hydrogen Sulfide Biosynthesis
AASLD LiverLearning®, Mengchun Li, 144487
DNA methylation level of non-cancerous liver tissue has potential for being a biomarker of multicentric recurrence of hepatocellular carcinoma
AASLD LiverLearning®, Takuji Torimura, 144244
Conditional survival estimate in patients with BCLC stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with or without concurrent radiotherapy
AASLD LiverLearning®, In Rae Cho, 144245
Oral pentamidine (VLX103) is an effective treatment for high fat diet-induced NASH in mice
AASLD LiverLearning®, Mark Czaja, 144503
Serum YKL-40 as a marker of liver fibrosis and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease
AASLD LiverLearning®, Yohei Mano, 144504
Real-life Adherence to BCLC Therapeutic Algorithm of Hepatocellular carcinoma in a Multicenter cohort from Argentina.
AASLD LiverLearning®, Federico Piñero, 144260
The efficacy of radiofrequency ablation combined with transcatheter hepatic chemoembolization for patients with BCLC stage B hepatocellular carcinoma: A multicenter retrospective study-propensity score matching
AASLD LiverLearning®, Masashi Hirooka, 144261
High-Fat Diet Induced Non-Alcoholic Steatohepatitis Impairs Liver Regeneration Post Hepatectomy
AASLD LiverLearning®, S.M.Touhidul Islam, 144519
Body Weight Is a Key Determinant of Alcohol-Induced Shifts in Intestinal Microbial Ecology
AASLD LiverLearning®, Puneet Puri, 144520
Disparities associated with out of Region Migration of Liver Transplant Candidates: A Case for Redistricting of UNOS Regions
AASLD LiverLearning®, George Cholankeril, 144276
Portal venous flow measured by ultrasound sonography after percutaneous transhepatic portal vein embolization is useful for prediction of hepatic hypertrophy
AASLD LiverLearning®, Shingo Shimada, 144277
Combined Lung and Liver Transplantation Offers Superior Outcomes Compared to Lung Transplantation Alone in Cirrhotics with Portal Hypertension Requiring Lung Transplantation
AASLD LiverLearning®, Jamak Modaresi Esfeh, 144292
Expanding the Utilization of Metabolic Livers for Domino Transplantation: Successful Domino Liver Transplant from a Patient with Propionic Acidemia
AASLD LiverLearning®, Nadia Ovchinsky Nadia, 144293
Acquired protein C deficiency: a major factor in the hypercoagulable state in patients with cirrhosis.
AASLD LiverLearning®, Armand Abergel, 144308
Outcomes in Patients with Severe Hepatic Encephalopathy and MELD 30 to 34 Justifies Exception to MELD 35 and Higher
AASLD LiverLearning®, George Cholankeril, 144309
Presence of hepatic encephalopathy, without ascites or variceal bleeding, is associated with worse outcomes after elective abdominal surgery
AASLD LiverLearning®, Ameish Govindarajan, 144324
Fecal Microbiota Transplantation from a Rationally Selected Donor is Safe in Patients with Recurrent Hepatic Encephalopathy: Preliminary Data from a Randomized Trial
AASLD LiverLearning®, Jasmohan S. Bajaj, 144325
The effect of hepatic arterial buffer response induced by partial splenic embolization on hepatic function in cirrhotic patients by Child-Pugh classification
AASLD LiverLearning®, Ryo Sasaki, 144340
The level of WFA+M2BP levels and alpha-fetoprotein levels are predicted hepatocellular carcinoma after sustained virologic responce with chronic hepatitis C patients
AASLD LiverLearning®, Ken Nishino, 144341
Hepatic Overexpression of Splicing Regulator Slu7 Ameliorates Alcoholic Steatosis in Mice via Modification of SIRT1 Alternative Splicing
AASLD LiverLearning®, Min You, 144100
T Cell Functionality in Chronic Hepatitis C Patients Treated With the Anti-miR-122 RG-101
AASLD LiverLearning®, Femke Stelma, 144356
Cell Death Biomarkers in Patients with Alcoholic Liver Disease
AASLD LiverLearning®, Benjamin Woolbright, 144101
Reversal of HCV-specific CD8+ T cell exhaustion after removal of cognate antigen
AASLD LiverLearning®, Pierre Tonnerre, 144357
Prediction And Impact Of Alcohol Abstinence After An Episode Of Alcoholic Hepatitis: A Long-Term Follow-Up Study
AASLD LiverLearning®, Jose Altamirano, 144102
Proteome Dynamics reveals that High Density Lipoprotein Dysfunction in Nonalcoholic Steatohepatitis is related to Increased Degradation of HDL proteins involved in Reverse Cholesterol Transport.
AASLD LiverLearning®, Takhar Kasumov, 144116
The mechanism of lncRNA IFI6 regulation of HCV infection
AASLD LiverLearning®, Xiao Liu, 144372
Impaired Adipocyte Autophagy Promotes White Adipocyte Browning And Protects Against Alcohol-Induced Liver Injury
AASLD LiverLearning®, Wen-Xing Ding, 144117
Plasma cytokines predict faster viral load decline in patients with chronic hepatitis C treated with direct-acting antivirals - an exploratory analysis
AASLD LiverLearning®, Cheng Wang, 144373
Establishment of a cellular model to study ethanol-induced lipophagy
AASLD LiverLearning®, Xiao-Ming Yin, 144118